Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAE+HAIC with Camrelizumab and Apatinib in Advanced HCC
NCT06363825Phase 2Recruiting
- Sponsor
- Fujian Medical University
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Fujian Medical University. Started Apr 2024; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06363825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06363825.